Co-Diagnostics Reports Solid First Quarter 2022 Financial Results marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company that develops and manufactures state-of-the-art diagnostics technology.
Co-Diagnostics Reports Strong Second Quarter 2021 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
SALT LAKE CITY, May 13, 2021 /PRNewswire/ Co-Diagnostics, Inc.
(NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the first quarter ended March 31, 2021.
First-Quarter 2021 Financial Results:
Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million, diluted EPS of $0.26
Revenue of $20.0 million, primarily due to sales of the Logix Smart™ COVID-19 Test
Gross profit increased to $16.8 million, representing 83.7% of consolidated revenue due to improved product mix as compared to the prior-year period
Operating income improved to $10.3 million over an operating loss in the prior-year quarter, due to continued strong revenue and gross profit